Skip to main content
Search
Search
United States
|
en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Brazil |
Português
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Mexico |
Español
United States |
English
Australia |
English
Bangladesh |
English
Hong Kong S.A.R. |
繁體中文
India |
English
Indonesia |
English
Japan |
日本語
Korea |
한국어
Mainland China |
中文
Malaysia |
English
Pakistan |
English
Philippines |
English
Singapore |
English
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Bulgaria |
Български
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hungary |
Magyar
Ireland |
English
Italy |
Italiano
Latvia |
Latvian
Lithuania |
Lithuanian
Netherlands |
Nederlands
Norway |
Norsk
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Serbia |
Srpski
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Türkiye |
Türkçe
United Kingdom |
English
Global |
English
Novartis Foundation |
English
Egypt |
English
Israel |
עברית
Saudi Arabia |
العربية
South Africa |
English
us
Choose Location
americas
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Australia |
English
Austria |
Deutsch
Bangladesh |
English
Belgium |
Français
Belgium |
Nederlands
Brazil |
Português
Bulgaria |
Български
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Egypt |
English
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hong Kong S.A.R. |
繁體中文
Hungary |
Magyar
India |
English
Indonesia |
English
Ireland |
English
Israel |
עברית
Italy |
Italiano
Japan |
日本語
Korea |
한국어
Latvia |
Latvian
Lithuania |
Lithuanian
Mainland China |
中文
Malaysia |
English
Mexico |
Español
Netherlands |
Nederlands
Norway |
Norsk
Global |
English
Novartis Foundation |
English
Pakistan |
English
Philippines |
English
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Saudi Arabia |
العربية
Serbia |
Srpski
Singapore |
English
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
South Africa |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Türkiye |
Türkçe
United Kingdom |
English
United States |
English
Menu
About
Novartis in the US
Company at a glance
By the numbers
Diversity and inclusion
Pay transparency-EPIC
Our code of ethics
Strategy
Diversity and inclusion
Ensuring equity
The spirit of inclusivity
Toward a better society
Parental leave
Standing for racial equity and justice as one Novartis
Novartis US EEO / D&I report 2021
Supplier diversity
People and culture
Products
US Country Coordinating Committee
External funding
Contact us
About
Patients and caregivers
Novartis commitment to patients and caregivers
Patient assistance
Diseases
Chronic spontaneous urticaria (CSU)
Hidradenitis suppurativa (HS)
Participating in clinical trials
Patient perspectives
Adverse event reporting
The STEP program
Sickle cell disease (SCD)
Program overview
Multiple sclerosis (MS)
Cancer
Application for funding to help address health disparities
Health disparities
Novartis patient support for oncology
Patient resources
Patients and caregivers
Healthcare professionals
Novartis pipeline
Novartis clinical trials
Adverse event reporting
Novartis patient support for oncology
HCP resources
Healthcare professionals
ESG
Ethical behavior
Code of ethics
SpeakUp
PhRMA Code on interactions with healthcare professionals
Business principles
Ethics, risk and compliance
Compliance program
State laws
Corporate integrity agreement
Payments to HCPs & HCOs
Enhanced verification request
Corporate responsibility
Population health
Novartis in society US reports
Novartis US Foundation
Environmental sustainability
People and communities
Beacon of hope
Beacon of hope: Measurable solutions for health equity
Paving the way for a brighter, more equitable future
ESG
News
News archive
Statements
Stories
Contacts
News
Careers
Career search
Meet the teams
Early career
Personal growth
How we work
Employee benefits
Diversity and inclusion
Awards & recognition
Careers
Home
Home
News
Novartis Investigational STAMP Inhibitor Asciminib (ABL001) Shows Superior MMR Rate To Bosulif®* In Chronic Myeloid Leukemia Trial
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
Dec 08, 2020
Reimagine Medicine
Innovation
AddToAny buttons
Share
Tweet
Share
Whatsapp
Linkedin
Email
Printable Links Block (Content)
Print
PDF